INT61264

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.61
First Reported 1996
Last Reported 2010
Negated 5
Speculated 1
Reported most in Body
Documents 36
Total Number 37
Disease Relevance 18.42
Pain Relevance 8.71

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Jun) nucleus (Jun) DNA binding (Jun)
transcription factor binding (Jun)
Anatomy Link Frequency
neurons 2
retina 1
hepatocytes 1
ACC neurons 1
central nervous system 1
Jun (Mus musculus)
Pain Link Frequency Relevance Heat
antidepressant 90 100.00 Very High Very High Very High
Inflammatory response 24 100.00 Very High Very High Very High
Kinase C 15 100.00 Very High Very High Very High
Sciatic nerve 5 100.00 Very High Very High Very High
Anterior cingulate cortex 53 99.52 Very High Very High Very High
cytokine 228 99.28 Very High Very High Very High
headache 2 98.96 Very High Very High Very High
adenocard 4 98.84 Very High Very High Very High
Central nervous system 43 98.82 Very High Very High Very High
rheumatoid arthritis 116 98.32 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 380 100.00 Very High Very High Very High
Stress 93 100.00 Very High Very High Very High
Cytomegalovirus Infection 10 100.00 Very High Very High Very High
Shock 9 100.00 Very High Very High Very High
Injury 59 99.78 Very High Very High Very High
Cold Sores 498 99.38 Very High Very High Very High
Adhesions 19 99.12 Very High Very High Very High
Infection 146 98.80 Very High Very High Very High
Necrosis 26 98.76 Very High Very High Very High
Rheumatoid Arthritis 118 98.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
AP-1 activity is regulated either directly or indirectly through reversible oxidation-reduction of critical cysteine residues [31,32]. c-Jun and c-fos have single conserved cysteine residues in their DNA-binding domains that undergo reversible redox reactions that alter their DNA-binding properties [33].
Regulation (regulated) of AP-1
1) Confidence 0.61 Published 2008 Journal BMC Pharmacol Section Body Doc Link PMC2632638 Disease Relevance 0.15 Pain Relevance 0
The independent regulation of those two immediate early genes has been previously shown in the chick retina [20].
Neg (independent) Regulation (regulation) of immediate early in retina
2) Confidence 0.60 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2774458 Disease Relevance 0.25 Pain Relevance 0.04
Expression is under the transcriptional control of a human cytomegalovirus immediate early promoter.
Regulation (control) of immediate early associated with cytomegalovirus infection
3) Confidence 0.60 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2483436 Disease Relevance 0.75 Pain Relevance 0.18
PENK is regulated by the c-jun amino-terminal kinase (JNK) signaling pathway, the crucial role of which is involved in the regulation of transcription factors, such as Jun and Fos.
Regulation (regulation) of Jun
4) Confidence 0.57 Published 2006 Journal Neurosci. Lett. Section Abstract Doc Link 16300887 Disease Relevance 0.15 Pain Relevance 0.20
It is often assumed that the site(s) of regulation of signaling through these pathways involves one or more of the numerous upstream kinases, such as MAP kinases, that control the activity of AP-1 and NF-?
Regulation (control) of AP-1
5) Confidence 0.45 Published 2008 Journal BMC Pharmacol Section Body Doc Link PMC2632638 Disease Relevance 0.08 Pain Relevance 0.13
In a number of studies, COX-2 induction by TPA in various cell types has been shown to involve signaling through AP-1 [38,39] and sometimes to involve both the AP-1 and NF-?
Regulation (signaling) of AP-1
6) Confidence 0.45 Published 2008 Journal BMC Pharmacol Section Body Doc Link PMC2632638 Disease Relevance 0.25 Pain Relevance 0.09
In a number of studies, COX-2 induction by TPA in various cell types has been shown to involve signaling through AP-1 [38,39] and sometimes to involve both the AP-1 and NF-?
Regulation (involve) of AP-1
7) Confidence 0.45 Published 2008 Journal BMC Pharmacol Section Body Doc Link PMC2632638 Disease Relevance 0.26 Pain Relevance 0.09
The effects of both these compounds AP-I (3-phenoxymethyl-4-phenyl-D2-1,2,4-triazoline-5-thione) and AP-II (3-phenoxymethyl-4-ethyl-D2-1,2,4-triazoline-5-thione) on the central nervous system (CNS) of mice were studied.
Regulation (effects) of AP-I in central nervous system associated with central nervous system
8) Confidence 0.44 Published 2004 Journal Acta Pol Pharm Section Abstract Doc Link 15909924 Disease Relevance 0 Pain Relevance 0.05
In support of plastic changes in the ACC after injury, activity-dependent immediate early genes, such as c-fos, Egr1, adenosine 3',5'-monophosphate response element binding protein (CREB) are activated in the ACC neurons after tissue inflammation or amputation [41,57].
Regulation (dependent) of immediate early in ACC neurons associated with adenocard, inflammation, injury, amputation and anterior cingulate cortex
9) Confidence 0.44 Published 2007 Journal Mol Pain Section Body Doc Link PMC1904186 Disease Relevance 1.11 Pain Relevance 0.61
The role of the PKC pathway or AP1 proteins in CRH gene regulation is still controversial.
Regulation (role) of AP1 associated with kinase c
10) Confidence 0.35 Published 2008 Journal Gene Regulation and Systems Biology Section Body Doc Link PMC2733102 Disease Relevance 0.08 Pain Relevance 0.27
When endotoxin was administered to mice in order to elicit a hepatic inflammatory response without necrosis, increases in c-jun expression occurred without accompanying changes in AP-1 activity, indicating a different mechanism of action.
Neg (without) Regulation (changes) of AP-1 associated with necrosis and inflammatory response
11) Confidence 0.27 Published 1996 Journal Res. Commun. Mol. Pathol. Pharmacol. Section Abstract Doc Link 8827825 Disease Relevance 0.58 Pain Relevance 0.56
After exercise time had shortened by > or =1.0 minute, we randomly assigned patients to receive either immediate-release ranolazine in 3 dosing regimens or placebo during each treatment period.
Regulation (receive) of immediate-release
12) Confidence 0.27 Published 1999 Journal Am. J. Cardiol. Section Abstract Doc Link 10404850 Disease Relevance 0.22 Pain Relevance 0.24
Under identical conditions, c-Jun mRNA levels were not altered.
Neg (not) Regulation (altered) of c-Jun mRNA
13) Confidence 0.21 Published 1997 Journal Cell. Immunol. Section Abstract Doc Link 9259765 Disease Relevance 0 Pain Relevance 0.71
An up-regulation of c-jun activity has been observed following neuronal injury [121].
Regulation (regulation) of c-jun in neuronal associated with injury
14) Confidence 0.21 Published 2010 Journal PPAR Research Section Body Doc Link PMC2748193 Disease Relevance 0.90 Pain Relevance 0.22
Up-regulation of stress response (MAFK, IKBZ, SOCS3) and early growth response (c-Myc, c-Jun, c-Fos, DUSP1 and 6) genes as assessed by RT-qPCR and/or microarray profiling was unchanged.
Regulation (regulation) of c-Jun associated with stress
15) Confidence 0.20 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2940888 Disease Relevance 0.19 Pain Relevance 0
Many of these adhesion molecules and their inducers are under the control of inflammatory response transcriptional factors such as NF kappa B and AP-1.
Regulation (control) of AP-1 associated with inflammatory response and adhesions
16) Confidence 0.16 Published 1996 Journal Eur. J. Immunol. Section Abstract Doc Link 8566054 Disease Relevance 0.90 Pain Relevance 0.41
Molecular studies revealed a marked up-regulation of the antiapoptotic heat shock proteins (Hsp) 27, 32, and 70 and of c-Jun in hepatocytes of stressed mice.
Regulation (regulation) of c-Jun in hepatocytes associated with shock
17) Confidence 0.15 Published 2004 Journal Hepatology Section Abstract Doc Link 14767996 Disease Relevance 1.67 Pain Relevance 0.14
Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
Regulation (controlled-release) of immediate-release associated with headache
18) Confidence 0.14 Published 2007 Journal J Clin Pharmacol Section Title Doc Link 17322147 Disease Relevance 0.19 Pain Relevance 0.10
Protandim diet alone did not affect either Jun D/Fra-1 or pJNK level significantly.


Neg (not) Regulation (affect) of Jun
19) Confidence 0.12 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2668769 Disease Relevance 0.59 Pain Relevance 0.13
ligands may be due to their ability to inhibit the activity of key transcription factors such as activator protein-1 (AP-1) and nuclear factor ?
Regulation (activity) of activator protein-1
20) Confidence 0.11 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526548 Disease Relevance 0.65 Pain Relevance 0.49

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox